| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/10/2011 | US20110034512 Indazole Compounds As CCR1 Receptor Antagonists |
| 02/10/2011 | US20110034511 Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
| 02/10/2011 | US20110034509 Beta-2-Adrenoreceptor Agonists |
| 02/10/2011 | US20110034508 Treatment of BDNF-related disorders using laquinimod |
| 02/10/2011 | US20110034502 Nalmefene prodrugs |
| 02/10/2011 | US20110034500 Spiroheterocyclic compounds and their uses as therapeutic agents |
| 02/10/2011 | US20110034499 Spiroindolines as modulators of chemokine receptors |
| 02/10/2011 | US20110034497 Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| 02/10/2011 | US20110034487 Cxcr3 antagonists |
| 02/10/2011 | US20110034485 Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture |
| 02/10/2011 | US20110034484 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands |
| 02/10/2011 | US20110034483 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease |
| 02/10/2011 | US20110034479 Deuterium-enriched alkyl sulfonamides |
| 02/10/2011 | US20110034475 1-aza-bicyclo[3.3.1]nonanes |
| 02/10/2011 | US20110034471 Novel combinations comprising a phoshodiesterase-5 inhibitor and their use |
| 02/10/2011 | US20110034470 Inhibitors of JNK |
| 02/10/2011 | US20110034458 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
| 02/10/2011 | US20110034455 Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| 02/10/2011 | US20110034447 Tdp-43-storing cell model |
| 02/10/2011 | US20110034446 R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof |
| 02/10/2011 | US20110034444 Selected cgrp antagonists, processes for preparing them and their use as pharmaceutical compositions |
| 02/10/2011 | US20110034443 Uses of substituted imidazoheterocycles |
| 02/10/2011 | US20110034442 Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders |
| 02/10/2011 | US20110034441 Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof |
| 02/10/2011 | US20110034438 Structural mimetics of proline-rich peptides and the pharmaceutical use thereof |
| 02/10/2011 | US20110034437 Isoxazolines as inhibitors of fatty acid amide hydrolase |
| 02/10/2011 | US20110034436 spirocyclic aminoquinolnes as gsk-3 inhibitors |
| 02/10/2011 | US20110034434 Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| 02/10/2011 | US20110034415 Walnut extracts for nutraceutical applications |
| 02/10/2011 | US20110034382 Use of liver growth factor (lgf) as a neural tissue regenerator |
| 02/10/2011 | US20110034375 Non-basic melanin concentrating hormone receptor-1 antagonists |
| 02/10/2011 | US20110033560 Preparation and a component intended to be added to a tobacco product |
| 02/10/2011 | US20110033539 Compositions and methods for preparing and using same |
| 02/10/2011 | US20110033538 Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof |
| 02/10/2011 | US20110033537 Sustained Drug Release Composition |
| 02/10/2011 | US20110033521 Molecules and Methods of Using Same for Treating MCP-1/CCR2 Associated Diseases |
| 02/10/2011 | US20110033506 Combination dosage form of low-dose modafinil and low-dose sildenafil |
| 02/10/2011 | US20110033504 Articles and methods for repairing damaged nervous tissue |
| 02/10/2011 | US20110033488 Agents and methods for treatment of anxiety disorders |
| 02/10/2011 | US20110033483 Single-chain multivalent binding proteins with effector function |
| 02/10/2011 | US20110033477 Method for diagnosing and treating chronic psychiatric illnesses and markers and targets for such methods |
| 02/10/2011 | US20110033469 Leukotriene b4 binding soluble lipocalin receptor from ixodes ricinus |
| 02/10/2011 | US20110033463 Apheresis, administration of agent, or combination thereof |
| 02/10/2011 | US20110033456 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 02/10/2011 | US20110033447 Methods for Treating Osteoarthritis Pain By Administering a Nerve Growth Factor Antagonist and Compositions Containing the Same |
| 02/10/2011 | US20110033426 Use of modified cells for the treatment of multiple sclerosis |
| 02/10/2011 | US20110033418 Treatment of diseases caused by viral infection |
| 02/10/2011 | CA2780829A1 Conformationally constrained, fully synthetic macrocyclic compounds |
| 02/10/2011 | CA2770409A1 Nitrogenous-ring acylguanidine derivative |
| 02/10/2011 | CA2769977A1 Benzylpiperidine compound |
| 02/10/2011 | CA2769464A1 Humanized anti-amyloid-.beta. oligomer antibody |
| 02/10/2011 | CA2769347A1 Methods for treatment of pain |
| 02/10/2011 | CA2769124A1 Conformationally constrained, fully synthetic macrocyclic compounds |
| 02/10/2011 | CA2768858A1 Bicyclic aryl sphingosine 1-phosphate analogs |
| 02/10/2011 | CA2767479A1 Use of xenon for treating hypersensitivity to pain |
| 02/10/2011 | CA2763956A1 Metabotropic glutamate receptor modulators |
| 02/09/2011 | EP2281828A2 Compositions comprising modified erythropoietin |
| 02/09/2011 | EP2281824A1 Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| 02/09/2011 | EP2281823A2 Anti-inflammatory and analgesic piperidine derivatives |
| 02/09/2011 | EP2281818A1 Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
| 02/09/2011 | EP2281572A1 West Nile Vaccine |
| 02/09/2011 | EP2281571A2 Outer membrane vesicle (omv) vaccine comprising n. meningitidids serogroup b outer membrane proteins |
| 02/09/2011 | EP2281570A2 Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins |
| 02/09/2011 | EP2281568A2 Uses of soluble CTLA4 mutant molecules |
| 02/09/2011 | EP2281566A1 Synergic 5'-methylthioadenosine combinations |
| 02/09/2011 | EP2281565A2 Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same |
| 02/09/2011 | EP2281561A2 Use of LCK inhibitors for treatment of immunologic diseases |
| 02/09/2011 | EP2281560A1 Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy |
| 02/09/2011 | EP2281559A1 Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| 02/09/2011 | EP2281558A1 Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors |
| 02/09/2011 | EP2281555A2 Once-a-day oxycodone formulations |
| 02/09/2011 | EP2280968A2 Pyrido [3, 4-b]indoles and methods of use |
| 02/09/2011 | EP2280967A2 Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity |
| 02/09/2011 | EP2280961A1 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands |
| 02/09/2011 | EP2280957A1 Pyridine derivatives used to treat orexin related disorders |
| 02/09/2011 | EP2280955A2 Crystalline form of 6-ý(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl¨pyridazin-3-amine |
| 02/09/2011 | EP2280951A2 Processes for the preparation of benzo-fused dioxin derivatives |
| 02/09/2011 | EP2280950A1 Process for the preparation of benzo-fused heteroaryl sulfamates and crystalline form of n- ( ( (2s) -6-chloro-2,3-dihydro-l,4-benzodioxin-2-yl) methyl-sulfamide |
| 02/09/2011 | EP2280946A1 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
| 02/09/2011 | EP2280945A1 Trisubstituted pyrazoles as acetylcholine receptor modulators |
| 02/09/2011 | EP2280941A1 (hetero-)aryl cyclohexane derivatives |
| 02/09/2011 | EP2280933A1 2 -aminotetralin derivatives as mu opioid receptor antagonists |
| 02/09/2011 | EP2280930A1 A novel and efficient method for the synthesis of an amino acid |
| 02/09/2011 | EP2280928A2 Vinyl substituted fatty acids |
| 02/09/2011 | EP2280722A2 Method of treating degenerative diseases |
| 02/09/2011 | EP2280719A2 Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy |
| 02/09/2011 | EP2280711A1 Methods, dosage forms, and kits for administering ziprasidone without food |
| 02/09/2011 | EP2280703A1 Use of npy y5 receptor antagonists for the prevention of psychostimulant and opioid abuse |
| 02/09/2011 | EP1943251B1 A1 adenosine receptor agonists |
| 02/09/2011 | EP1931656B1 Novel drugs for dementia |
| 02/09/2011 | EP1883451B9 Substituted indole compounds having nos inhibitory activity |
| 02/09/2011 | EP1750808B1 Myricitrin compounds for treating sleeping disorders |
| 02/09/2011 | EP1685100B1 Novel 1, 3-disubstituted azetidine derivatives for use as 5ht2a receptor ligands |
| 02/09/2011 | EP1664005B1 Thiazole derivatives as cannabinoid receptor modulators |
| 02/09/2011 | EP1640367B1 Isoquinoline -1,3,4-trione, the synthetic method and the use thereof |
| 02/09/2011 | EP1451192B1 Novel crystalline compound |
| 02/09/2011 | EP1405638B1 Pharmaceutical composition comprising quinuclidin-3'-yl 1-phenyl-1,2,3,4,-tetrahydroisoquinoline-2-carboxylate for treatment of interstitial cystitis and/or abacterial prostatitis |
| 02/09/2011 | EP1379508B9 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| 02/09/2011 | EP1370276B1 Intercellular communication facilitating compounds and their medical use |
| 02/09/2011 | CN1732955B Pharmaceutical composition making anemarrhena total sapogenin as active ingredient, its preparation method and use |